Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

KOD

Kodiak Sciences Inc

Jun 20 • 04:00PM ET

3.62

Dollar change +0.09
Percentage change 2.55	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN NVAX VRTX ALNY NBIX BIIB BLUE CRSP GILD IONS

| Held by: VTI IWM VXF IWN FESM VTWO SCHA DFAT AVSC IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.62	Insider Own	7.83%	Shs Outstand	52.75M	Perf Week	-1.63%
Market Cap	191.00M	Forward P/E	-	EPS next Y	-3.27	Insider Trans	-0.02%	Shs Float	48.63M	Perf Month	-10.84%
Income	-190.63M	PEG	-	EPS next Q	-1.07	Inst Own	79.28%	Short Float	4.68%	Perf Quarter	12.77%
Sales	0.00M	P/S	-	EPS this Y	-18.63%	Inst Trans	3.73%	Short Ratio	5.55	Perf Half Y	-55.42%
Book/sh	2.06	P/B	1.75	EPS next Y	17.82%	ROA	-52.04%	Short Interest	2.28M	Perf Year	34.57%
Cash/sh	2.63	P/C	1.38	EPS next 5Y	-1.70%	ROE	-108.92%	52W Range	1.92 - 11.60	Perf YTD	-63.62%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-21.78%	ROIC	-71.79%	52W High	-68.79%	Beta	2.28
Dividend TTM	-	Quick Ratio	4.62	Sales past 5Y	-	Gross Margin	-	52W Low	88.54%	ATR (14)	0.37
Dividend Ex-Date	-	Current Ratio	4.62	EPS Y/Y TTM	18.41%	Oper. Margin	-	RSI (14)	46.82	Volatility	3.43% 4.66%
Employees	109	Debt/Eq	1.54	Sales Y/Y TTM	-	Profit Margin	-	Recom	3.80	Target Price	7.25
Option/Short	Yes / Yes	LT Debt/Eq	1.44	EPS Q/Q	-32.92%	Payout	-	Rel Volume	0.60	Prev Close	3.53
Sales Surprise	-	EPS Surprise	-21.94%	Sales Q/Q	-	Earnings	May 14 AMC	Avg Volume	410.29K	Price	3.62
SMA20	-3.58%	SMA50	-1.17%	SMA200	-23.18%	Trades		Volume	244,214	Change	2.55%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-24	Upgrade	Jefferies	Hold → Buy	$20
Sep-05-24	Initiated	H.C. Wainwright	Neutral	$3
Dec-11-23	Resumed	Goldman	Sell	$2
Nov-17-23	Upgrade	CapitalOne	Equal Weight → Overweight	$7 → $12
Jul-27-23	Downgrade	UBS	Buy → Neutral	$15 → $4
Jul-25-23	Downgrade	JP Morgan	Neutral → Underweight
Jul-25-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Jul-24-23	Downgrade	Jefferies	Buy → Hold
Jul-24-23	Downgrade	CapitalOne	Overweight → Equal Weight	$7
Nov-15-22	Initiated	CapitalOne	Overweight	$24
Aug-02-22	Downgrade	Citigroup	Neutral → Sell	$6
Feb-24-22	Downgrade	JP Morgan	Overweight → Neutral	$90 → $21
Feb-11-22	Initiated	Goldman	Buy	$70
Feb-02-22	Upgrade	JP Morgan	Neutral → Overweight	$124 → $90
May-11-21	Upgrade	ROTH Capital	Neutral → Buy	$155 → $149
Mar-12-21	Initiated	Evercore ISI	Outperform
Mar-01-21	Downgrade	Barclays	Equal Weight → Underweight	$52 → $90
Feb-17-21	Downgrade	ROTH Capital	Buy → Neutral	$133 → $155
Jan-25-21	Downgrade	BMO Capital Markets	Outperform → Market Perform	$145 → $148
Dec-17-20	Initiated	Berenberg	Buy	$156

Show Previous Ratings

Jun-13-25 11:30AM	Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report? (Zacks) +5.43%
May-29-25 09:32PM	Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference (PR Newswire)
May-15-25 11:04AM	Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus (Zacks) -15.48%
May-14-25 04:15PM	Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results (PR Newswire)
May-01-25 11:43PM	Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases (PR Newswire) +6.90%
09:35AM	Loading…
Apr-01-25 09:35AM	Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences (KOD) (Zacks) -8.73%
Mar-28-25 09:45AM	Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
Mar-27-25 04:01PM	Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Mar-26-25 03:58PM	Is Kodiak Sciences Inc. (KOD) The Hot Biotech Stock Under $5? (InsiderMonkey) -6.08%
Mar-10-25 04:39PM	Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy (PR Newswire)
Feb-04-25 07:30AM	Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025 (PR Newswire)
Jan-13-25 04:26PM	Heres Why Kodiak Sciences Inc. (KOD) Is Skyrocketing (Insider Monkey) -6.13%
Jan-07-25 06:00AM	Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-09-24 09:18PM	Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic Diseases (PR Newswire) +29.63%
12:33PM	Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock (Benzinga)
09:55AM	Loading…
Nov-25-24 09:55AM	Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Nov-14-24 04:01PM	Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results (PR Newswire)
Nov-11-24 06:15AM	Kodiak Sciences to Participate in Upcoming Investor Conferences (PR Newswire) +8.54%
Oct-14-24 05:35PM	Kodiak Sciences to Present at Innovate Retina 2024 (PR Newswire)
Sep-23-24 06:00AM	Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time (PR Newswire)
Sep-17-24 04:05PM	Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City (PR Newswire)
Sep-13-24 11:30AM	Why Is Kodiak Sciences (KOD) Down 8.1% Since Last Earnings Report? (Zacks) +13.87%
Aug-16-24 10:42AM	Kodiak (KOD) Q2 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
Aug-14-24 09:54PM	KOD Stock Earnings: Kodiak Sciences Beats EPS for Q2 2024 (InvestorPlace)
04:01PM	Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results (PR Newswire)
Jul-10-24 12:00PM	All You Need to Know About Kodiak Sciences (KOD) Rating Upgrade to Buy (Zacks)
Jun-20-24 08:23AM	Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio? (Zacks)
Jun-14-24 11:30AM	Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report? (Zacks)
May-29-24 04:36PM	Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences (PR Newswire)
May-16-24 12:51PM	Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
10:55PM	Loading…
May-15-24 10:55PM	KOD Stock Earnings: Kodiak Sciences Beats EPS for Q1 2024 (InvestorPlace)
04:01PM	Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results (PR Newswire)
May-14-24 07:31AM	Kodiak Sciences dosing subjects in Phase III trial of diabetic retinopathy drug (Clinical Trials Arena)
May-13-24 07:32PM	Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy (PR Newswire) +6.09%
May-02-24 04:30PM	Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform (PR Newswire)
Apr-04-24 12:09PM	Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks (Zacks)
Apr-01-24 05:04PM	Kodiak Sciences Inc. (NASDAQ:KOD) Q4 2023 Earnings Call Transcript (Insider Monkey) -15.40%
12:00PM	Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus (Zacks)
Mar-29-24 10:36AM	Q4 2023 Kodiak Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-28-24 11:53AM	KOD Stock Earnings: Kodiak Sciences Misses EPS for Q4 2023 (InvestorPlace) -29.40%
08:32AM	Kodiak Sciences Inc (KOD) Posts Q4 and Full Year 2023 Financial Results (GuruFocus.com)
06:30AM	Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Mar-26-24 06:15AM	Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024 (PR Newswire) +16.01%
Jan-30-24 06:30AM	Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting (PR Newswire) -8.58%
Jan-04-24 04:15PM	Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-14-23 11:30AM	Kodiak Sciences Inc. (KOD) Up 43.6% Since Last Earnings Report: Can It Continue? (Zacks) +6.21%
Nov-21-23 04:15PM	Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference (PR Newswire) -7.41% +6.67%
Nov-15-23 08:00AM	Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline Updates (Zacks) +5.21%
Nov-14-23 06:09PM	Kodiak Sciences Inc (KOD) Reports Q3 2023 Financial Results: Net Loss Narrows, R&D Expenses ... (GuruFocus.com) +6.67%
04:01PM	Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights (PR Newswire)
Nov-06-23 05:00AM	Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission (PR Newswire) -13.56%
Nov-01-23 11:21PM	KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING (PR Newswire) +6.21% +37.01%
Oct-17-23 01:44AM	Lonza Warns on 2024 Profitability Hit From Lost Moderna Revenue (The Wall Street Journal)
Oct-11-23 06:00AM	Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society (PR Newswire)
Sep-13-23 11:30AM	Kodiak Sciences Inc. (KOD) Down 19.9% Since Last Earnings Report: Can It Rebound? (Zacks)
Sep-08-23 06:00AM	Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (PR Newswire)
Sep-07-23 06:00AM	New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion (PR Newswire)
Aug-16-23 10:26AM	Kodiak (KOD) Q2 Earnings Miss, New Lead Candidate in Focus (Zacks)
Aug-14-23 07:31PM	While dollars continue to flow into biotech, companies cut more jobs (American City Business Journals) -6.81% -9.97%
04:01PM	Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights (PR Newswire)
08:34AM	Should You Buy Kodiak Sciences (KOD) Ahead of Earnings? (Zacks)
07:15AM	3 Biotech Stocks Poised to Beat Q2 Earnings Estimates (Zacks)
Aug-02-23 10:09AM	Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards? (Zacks) +5.33%
Jul-27-23 02:30AM	4 big analyst cuts: Carvana 'well above our increased target,' says Morgan Stanley (Investing.com) -10.49%
Jul-26-23 06:42AM	Kodiak Sciences Inc. (NASDAQ:KOD) Is Expected To Breakeven In The Near Future (Simply Wall St.) -10.74%
Jul-25-23 09:16AM	Kodiak (KOD) Down as Late-Stage DME Studies Fail (Zacks) -7.98%
Jul-24-23 06:26AM	CORRECTED-UPDATE 1-Kodiak Sciences scraps development of eye disorder drug (Reuters) -45.88%
06:09AM	Kodiak Sciences scraps development of eye disorder drug (Reuters)
06:00AM	Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program (PR Newswire)
Jun-14-23 11:30AM	Why Is Kodiak Sciences Inc. (KOD) Up 62.9% Since Last Earnings Report? (Zacks)
May-30-23 04:15PM	Kodiak Sciences to Present at Upcoming Investor Conferences (PR Newswire)
11:14AM	Kodiak (KOD) Advances With Tarcocimab Amid Stiff Competition (Zacks)
May-16-23 07:44AM	Kodiak's (KOD) Q1 Earnings Miss, Pipeline in Focus, Stock Up (Zacks) +10.44%
May-15-23 04:01PM	Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights (PR Newswire) +12.61%
Apr-27-23 11:30AM	Why Is Kodiak Sciences Inc. (KOD) Down 26.3% Since Last Earnings Report? (Zacks)
Apr-21-23 07:30AM	Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting (PR Newswire)
Apr-11-23 06:29AM	We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate (Simply Wall St.)
Apr-04-23 01:16PM	Kodiak (KOD) Treats First Patient in Diabetic Macular Edema Study (Zacks) -8.56%
Apr-03-23 11:38AM	Kodiak Sciences (KOD) Shares are Up 26% in a Week: Here's Why (Zacks) -12.34%
07:30AM	Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases (PR Newswire)
Mar-28-23 04:08PM	Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights (PR Newswire) +23.27%
Mar-01-23 05:55AM	In the wake of Kodiak Sciences Inc.'s (NASDAQ:KOD) latest US$39m market cap drop, institutional owners may be forced to take severe actions (Simply Wall St.)
Feb-09-23 07:30AM	Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting (PR Newswire)
Jan-04-23 07:00AM	Kodiak Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire) +9.40%
Dec-09-22 11:30AM	Kodiak Sciences Inc. (KOD) Up 1% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-30-22 09:55AM	Does Kodiak Sciences Inc. (KOD) Have the Potential to Rally 87% as Wall Street Analysts Expect? (Zacks)
Nov-16-22 04:30PM	Kodiak Sciences to Present at the Evercore ISI 5th Annual HealthCONx Conference (PR Newswire)
Nov-14-22 09:55AM	Wall Street Analysts See a 72% Upside in Kodiak Sciences Inc. (KOD): Can the Stock Really Move This High? (Zacks)
Nov-10-22 02:17PM	Kodiak Sciences' (KOD) Q3 Earnings Beat, Eye Candidate in Focus (Zacks) +5.79%
Nov-09-22 04:01PM	Kodiak Sciences Announces Third Quarter 2022 Financial Results and Recent Business Highlights (PR Newswire)
Nov-02-22 06:24AM	We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully (Simply Wall St.)
Sep-22-22 06:06AM	Owning 44% shares,institutional owners seem interested in Kodiak Sciences Inc. (NASDAQ:KOD), (Simply Wall St.)
Sep-08-22 11:30AM	Why Is Kodiak Sciences Inc. (KOD) Down 23.8% Since Last Earnings Report? (Zacks)
Sep-07-22 04:05PM	Kodiak Sciences to Present at the 2022 Morgan Stanley Healthcare Conference (PR Newswire)
Aug-26-22 01:34PM	Kodiak Sciences (KOD) Rises 60% in Past 3 Months: Here's Why (Zacks)
Aug-19-22 12:32PM	Kodiak Sciences (KOD) Focuses on Developing Eye Drug Tarcocimab (Zacks) -8.17%
Aug-18-22 05:47PM	Kodiak Sciences Announces Upcoming Presentations of Tarcocimab Tedromer (KSI-301) Phase 3 BEACON Study Results in Retinal Vein Occlusion (RVO) (PR Newswire)
Aug-10-22 10:57AM	Kodiak Sciences (KOD) Q2 Earnings Beat, Eye Candidate in Focus (Zacks) +14.47%
Aug-09-22 04:33PM	Kodiak Sciences Announces Second Quarter 2022 Financial Results and Recent Business Highlights (PR Newswire)
Aug-08-22 08:39AM	Kodiak's Eye Disease Candidate At Par With Regeneron's Eylea In Visual Acuity Gains (Benzinga) +14.07%

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BORGESON JOHN A.	See Remarks	Jun 17 '25	Sale	3.65	723	2,640	183,316	Jun 17 08:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KOD

Kodiak Sciences Inc

Upgrade your FINVIZ experience